| |
|
|
|
|
|
|
|||
|
Blood, 15 August 2007, Vol. 110, No. 4, pp. 1330-1333. Prepublished online as a Blood First Edition Paper on May 11, 2007; DOI 10.1182/blood-2007-03-081133.
NEOPLASIA Interleukin-6–dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer1 Institute of Clinical Immunology and Transfusion Medicine, Medical Faculty, University of Leipzig, Leipzig; 2 Bioinformatics Group, Department of Computer Science, University of Leipzig, Leipzig; 3 Fraunhofer Institute of Cell Therapy and Immunology, Leipzig; 4 Division of Stem Cell Transplantation and Immunotherapy, 2nd Medical Department, University Hospital Schleswig-Holstein Campus Kiel, Kiel; 5 Interdisciplinary Center for Clinical Studies, University of Leipzig, Germany Signal transducer and activator of transcription 3 (Stat3) is implicated in the pathogenesis of many malignancies and essential for IL-6–dependent survival and growth of multiple myeloma cells. Here, we demonstrate that the gene encoding oncogenic microRNA-21 (miR-21) is controlled by an upstream enhancer containing 2 Stat3 binding sites strictly conserved since the first observed evolutionary appearance of miR-21 and Stat3. MiR-21 induction by IL-6 was strictly Stat3 dependent. Ectopically raising miR-21 expression in myeloma cells in the absence of IL-6 significantly reduced their apoptosis levels. These data provide strong evidence that miR-21 induction contributes to the oncogenic potential of Stat3.
Related Article in Blood Online:
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||